Stocks News

LAST PRICE
0.2800
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
0.2700/ 59
Ask / Lots
0.2700/ 4
Open / Previous Close
--- / 0.2800
Day Range
---
52 Week Range
Low 0.0650
High 0.3500
Volume
---
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 14, 2024
- PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License, from 9:20AM ET on Thursday Nov 14, 2024 by Dow Jones
  9:20AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MDMA
  
  PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
  
  TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo(TM) MDMA and novel derivatives of MDMA (MDXX class molecules), has signed a Letter of Intent with a research institution to provide its LaNeo MDMA in exchange for a full and perpetual license to the efficacy and safety data generated by the trial.
Nov 7, 2024
- PharmAla to supply LaNeo MDMA for Clinical Trial at Yale, from 9:20AM ET on Thursday Nov 07, 2024 by Dow Jones
  9:20AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: MDMA
  
  PharmAla to supply LaNeo MDMA for Clinical Trial at Yale
  
  TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo(TM) MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a clinical trial at Yale University.

Nov 20, 2024
- Sirona Biochem Says TFC-1326 Reduced Visible Signs of Skin Aging in Pilot Clinical Study, from 4:51PM ET on Wednesday Nov 20, 2024 by MT Newswires
  4:51PM ET on Wednesday Nov 20, 2024 by MT Newswires
  Companies Mentioned: SBM
- -- Sirona Biochem Brief: Announcing Publication of "Groundbreaking Study" on TFC-1326 Compound in the Journal of Cosmetic Dermatology, from 4:32PM ET on Wednesday Nov 20, 2024 by MT Newswires
  4:32PM ET on Wednesday Nov 20, 2024 by MT Newswires
  Companies Mentioned: SBM
- Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology, from 4:30PM ET on Wednesday Nov 20, 2024 by Dow Jones
  4:30PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: SBM
Nov 14, 2024
- Defence Therapeutics Announces Securities for Debenture Financing, from 7:31PM ET on Thursday Nov 14, 2024 by Newsfile
  7:31PM ET on Thursday Nov 14, 2024 by Newsfile
  Companies Mentioned: DTCFF
- Defence Therapeutics Announces Securities for Debenture Financing, from 7:31PM ET on Thursday Nov 14, 2024 by Dow Jones
  7:31PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: DTC
Nov 13, 2024
- Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors, from 3:16AM ET on Wednesday Nov 13, 2024 by Newsfile
  3:16AM ET on Wednesday Nov 13, 2024 by Newsfile
  Companies Mentioned: DTCFF
- Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors, from 3:16AM ET on Wednesday Nov 13, 2024 by Dow Jones
  3:16AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: DTC
Nov 7, 2024
- Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update, from 8:16AM ET on Thursday Nov 07, 2024 by Newsfile
  8:16AM ET on Thursday Nov 07, 2024 by Newsfile
  Companies Mentioned: SNANF
- Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update, from 8:16AM ET on Thursday Nov 07, 2024 by Dow Jones
  8:16AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: SONA
Nov 4, 2024
- Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs, from 6:17PM ET on Monday Nov 04, 2024 by Dow Jones
  6:17PM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: DTC

Pharmala Biotech Holdings Inc
Canadian Securities Exchange:MDMACanadaView on Grey Market

Search Criteria

Nov 14, 2024

PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License, from 9:20AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 7, 2024

PharmAla to supply LaNeo MDMA for Clinical Trial at Yale, from 9:20AM ET on Thursday Nov 07, 2024 by Dow Jones

Peers Headlines

Nov 20, 2024

Sirona Biochem Says TFC-1326 Reduced Visible Signs of Skin Aging in Pilot Clinical Study, from 4:51PM ET on Wednesday Nov 20, 2024 by MT Newswires

-- Sirona Biochem Brief: Announcing Publication of "Groundbreaking Study" on TFC-1326 Compound in the Journal of Cosmetic Dermatology, from 4:32PM ET on Wednesday Nov 20, 2024 by MT Newswires

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology, from 4:30PM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 14, 2024

Defence Therapeutics Announces Securities for Debenture Financing, from 7:31PM ET on Thursday Nov 14, 2024 by Newsfile

Defence Therapeutics Announces Securities for Debenture Financing, from 7:31PM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors, from 3:16AM ET on Wednesday Nov 13, 2024 by Newsfile

Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors, from 3:16AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 7, 2024

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update, from 8:16AM ET on Thursday Nov 07, 2024 by Newsfile

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update, from 8:16AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 4, 2024

Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs, from 6:17PM ET on Monday Nov 04, 2024 by Dow Jones